CN1324024C - 取代的噻吩、其制备方法、其作为药物或诊断试剂的用途和含有它们的药物 - Google Patents

取代的噻吩、其制备方法、其作为药物或诊断试剂的用途和含有它们的药物 Download PDF

Info

Publication number
CN1324024C
CN1324024C CNB038128462A CN03812846A CN1324024C CN 1324024 C CN1324024 C CN 1324024C CN B038128462 A CNB038128462 A CN B038128462A CN 03812846 A CN03812846 A CN 03812846A CN 1324024 C CN1324024 C CN 1324024C
Authority
CN
China
Prior art keywords
chloro
methyl
benzimidazolyl
hydrogen
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038128462A
Other languages
English (en)
Chinese (zh)
Other versions
CN1659163A (zh
Inventor
H-J·朗
U·海内尔特
A·霍夫迈斯特
K·维尔特
M·格克尔
M·布莱希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CN1659163A publication Critical patent/CN1659163A/zh
Application granted granted Critical
Publication of CN1324024C publication Critical patent/CN1324024C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB038128462A 2002-06-04 2003-05-26 取代的噻吩、其制备方法、其作为药物或诊断试剂的用途和含有它们的药物 Expired - Fee Related CN1324024C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10224892A DE10224892A1 (de) 2002-06-04 2002-06-04 Substituierte Thiophene, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10224892.3 2002-06-04

Publications (2)

Publication Number Publication Date
CN1659163A CN1659163A (zh) 2005-08-24
CN1324024C true CN1324024C (zh) 2007-07-04

Family

ID=29557542

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038128462A Expired - Fee Related CN1324024C (zh) 2002-06-04 2003-05-26 取代的噻吩、其制备方法、其作为药物或诊断试剂的用途和含有它们的药物

Country Status (32)

Country Link
EP (1) EP1513834B1 (enExample)
JP (1) JP4511924B2 (enExample)
KR (1) KR101087966B1 (enExample)
CN (1) CN1324024C (enExample)
AR (1) AR040239A1 (enExample)
AT (1) ATE320425T1 (enExample)
AU (1) AU2003273553B2 (enExample)
BR (1) BR0311548A (enExample)
CA (1) CA2488242C (enExample)
CR (1) CR7577A (enExample)
DE (2) DE10224892A1 (enExample)
DK (1) DK1513834T3 (enExample)
EC (1) ECSP045471A (enExample)
ES (1) ES2258722T3 (enExample)
HR (1) HRP20041153A2 (enExample)
IL (1) IL165519A (enExample)
MA (1) MA27204A1 (enExample)
ME (1) MEP27608A (enExample)
MX (1) MXPA04011986A (enExample)
MY (1) MY129832A (enExample)
NO (1) NO329351B1 (enExample)
OA (1) OA12827A (enExample)
PE (1) PE20040534A1 (enExample)
PL (1) PL372589A1 (enExample)
PT (1) PT1513834E (enExample)
RS (1) RS51141B (enExample)
RU (1) RU2315766C2 (enExample)
TN (1) TNSN04240A1 (enExample)
TW (1) TWI283675B (enExample)
UA (1) UA77551C2 (enExample)
WO (1) WO2003101984A1 (enExample)
ZA (1) ZA200409095B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10323701A1 (de) 2003-05-22 2004-12-23 Aventis Pharma Deutschland Gmbh Verfahren zur Synthese heterocyclischer Verbindungen
US20040242560A1 (en) 2003-05-22 2004-12-02 Aventis Pharma Deutschland Gmbh Process for synthesizing heterocyclic compounds
IN2006CH00378A (en) 2003-06-30 2007-05-11 Sumitomo Chemical Co Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst
WO2008051533A2 (en) * 2006-10-25 2008-05-02 Takeda Pharmaceutical Company Limited Benzimidazole compounds
WO2010025856A1 (en) 2008-09-02 2010-03-11 Sanofi-Aventis Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
RU2373929C1 (ru) * 2008-11-11 2009-11-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) Корректор системы гемостаза, проявляющий ингибирующее действие на адгезивно-агрегационную функцию тромбоцитов для профилактики патологического тромбообразования
WO2011058139A1 (en) * 2009-11-12 2011-05-19 Selvita Sp. Z O. O. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
RU2518740C1 (ru) * 2013-03-22 2014-06-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ДИГИДРОХЛОРИД 2-(3,4-МЕТИЛЕНДИОКСИФЕНИЛ)-9-МОРФОЛИНОЭТИЛИМИДАЗО[1,2-a]БЕНЗИМИДАЗОЛА
MX375386B (es) 2014-07-25 2025-03-06 Taisho Pharmaceutical Co Ltd Compuesto de feniltetrahidroisoquinolina sustituido con heteroarilo.
KR102840252B1 (ko) * 2023-04-27 2025-07-30 한국화학연구원 시아노벤즈이미다졸 유도체, 약제학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
WO2025067474A1 (zh) * 2023-09-28 2025-04-03 四川大学华西医院 一种含吡啶的化合物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758476A (en) * 1969-08-13 1973-09-11 Hoechst Ag 2-(thienyl-3'-amino)-1,3-diazacycloalkenes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6915362D0 (pt) * 1969-08-16 1973-01-04 Hoechst Ag Processo para a preparacao de 2(tienil-3-amino)1,3-diazacicloalquenos
DE2830279A1 (de) * 1978-07-10 1980-01-31 Boehringer Sohn Ingelheim 2-eckige klammer auf n-(2'-chlor-4'- methyl-thienyl-3')-n-(cyclopropylmethyl)- amino eckige klammer zu-imidazolin-(2), dessen saeureadditionssalze, dieses enthaltende arzneimittel und verfahren zu seiner herstellung
US5395847A (en) * 1993-12-02 1995-03-07 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
CA2338275A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
DE19921883A1 (de) * 1999-05-12 2000-11-16 Bayer Ag Substituierte Thienocycloalk(en)ylamino-1,3,5-triazine
DE19960204A1 (de) * 1999-12-14 2001-06-28 Aventis Pharma Gmbh Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EA007987B1 (ru) * 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758476A (en) * 1969-08-13 1973-09-11 Hoechst Ag 2-(thienyl-3'-amino)-1,3-diazacycloalkenes

Also Published As

Publication number Publication date
TNSN04240A1 (en) 2007-03-12
CA2488242A1 (en) 2003-12-11
PE20040534A1 (es) 2004-10-25
AU2003273553B2 (en) 2008-12-04
ES2258722T3 (es) 2006-09-01
RU2004138812A (ru) 2005-07-20
DE10224892A1 (de) 2003-12-18
TW200406409A (en) 2004-05-01
ECSP045471A (es) 2005-01-28
NO329351B1 (no) 2010-10-04
MEP27608A (en) 2010-06-10
MXPA04011986A (es) 2005-03-07
IL165519A (en) 2010-05-31
CN1659163A (zh) 2005-08-24
TWI283675B (en) 2007-07-11
DE50302673D1 (de) 2006-05-11
EP1513834B1 (de) 2006-03-15
CR7577A (es) 2005-06-16
IL165519A0 (en) 2006-01-15
JP4511924B2 (ja) 2010-07-28
MY129832A (en) 2007-05-31
KR101087966B1 (ko) 2011-12-01
PT1513834E (pt) 2006-06-30
RS103804A (sr) 2006-12-15
HK1076460A1 (en) 2006-01-20
ZA200409095B (en) 2005-05-10
DK1513834T3 (da) 2006-07-17
WO2003101984A1 (de) 2003-12-11
UA77551C2 (en) 2006-12-15
BR0311548A (pt) 2005-04-12
HRP20041153A2 (en) 2005-06-30
MA27204A1 (fr) 2005-01-03
EP1513834A1 (de) 2005-03-16
CA2488242C (en) 2011-08-02
JP2005533038A (ja) 2005-11-04
RS51141B (sr) 2010-10-31
KR20050005532A (ko) 2005-01-13
AU2003273553A1 (en) 2003-12-19
ATE320425T1 (de) 2006-04-15
AR040239A1 (es) 2005-03-23
RU2315766C2 (ru) 2008-01-27
NO20045504L (no) 2005-01-25
PL372589A1 (en) 2005-07-25
OA12827A (en) 2006-07-11

Similar Documents

Publication Publication Date Title
CN1158256C (zh) 吡咯烷衍生物-ccr-3受体拮抗剂
CN100337626C (zh) 酰化的、杂芳基－稠合的环烯基胺和它们作为药物的用途
CN1163484C (zh) 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
CN1462268A (zh) 取代的肉桂酸胍化物、其制备方法、其作为药物的应用、以及含有这些化合物的药物
CN1040986A (zh) 环烷基取代的戊二酰胺衍生物的制备
CN1324024C (zh) 取代的噻吩、其制备方法、其作为药物或诊断试剂的用途和含有它们的药物
CN1674893A (zh) 苯并咪唑衍生物
CN1617856A (zh) 取代的4－苯基四氢异喹啉、其制备方法、其用作药物的用途以及含有它们的药物
CN1478081A (zh) 取代的2-苯胺基苯并咪唑及其作为nhe抑制剂的用途
CN1290833C (zh) 用于治疗梗塞和心绞痛的nhe－1抑制剂n－((3－氧代－2,3－二氢－1h－异吲哚－1－基)乙酰基)胍衍生物
CN1151735A (zh) 苯并环烷基唑硫酮衍生物
CN1798737A (zh) 取代的4－苯基四氢异喹啉、其制备方法、其作为药物的用途和含有这类化合物的药物
HK1042691A1 (zh) 磺酰胺异羟肟酸脂
CN1110484C (zh) 2－(芳基苯基)氨基－咪唑啉衍生物
CN1210251C (zh) 取代的降冰片基氨基衍生物,其制备和用途以及包含它们的药物
CN1665503A (zh) 杂芳烃甲酰胺作为多巴胺－d3配体用于治疗中枢神经系统疾病的用途
CN88101782A (zh) 抗心律不齐药
CN1211370C (zh) 具有联苯基磺酰基取代基的咪唑衍生物、其制备方法及其作为药物或诊断剂的应用
CN1871222A (zh) Ccr3受体拮抗剂
CN1890228A (zh) α－氨基酸衍生物及其作为药物的应用
CN1823059A (zh) 作为治疗肥胖和CNS疾病的选择性D<sub>1</sub>/D<sub>5</sub>受体拮抗剂的5－H－苯并[D]萘并[2,1－B]氮杂䓬衍生物
CN1665506A (zh) 作为ccr－3受体拮抗剂ⅸ的2,5－取代的嘧啶衍生物
CN1845926A (zh) 取代的噻吩并咪唑、其制备方法、其作为药物或诊断剂的用途和包含它们的药物
CN1229371C (zh) 苯并吡喃胍衍生物,其制备方法,及其药物组合物
HK1076460B (en) Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1076460

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070704

Termination date: 20180526